Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
A strongly positive crossmatch has long been considered an absolute contraindication to
kidney transplantation and most patients with anti-human leukocyte antigen (HLA) antibody
never were able to receive a kidney transplant. Over the past decade, significant progress
has been made in overcoming early antibody-mediated renal allograft injury. Our group has
performed more than 200 such transplants providing the possibility of transplant to
previously untransplantable patients. Despite our best efforts, transplantation in these
patients is still complicated by a high rate of acute humoral rejection (AHR).
Patients included in this study will be those who have demonstrable anti-HLA antibody
specific for their living donor. It is our hypothesis that blockade of terminal complement
activation at the time of transplant in combination with our current protocols will reduce
the incidence of AHR in patients with anti-donor HLA antibody.